Table 2 Seroconversion and seroprotection rates 4Â weeks after seasonal influenza vaccination in patients with COPD
From: Seasonal influenza vaccination in patients with COPD: a systematic literature review
Reference | Country | Influenza season | Vaccine type | Influenza type/subtype | Immunogenicity outcome | |
|---|---|---|---|---|---|---|
|  | Percentage with ≥4-fold increase of antibody titres (95% CI) (n/N) | Percentage with antibody titre ≥1:40 (95% CI) (n/N) | ||||
Nath et al., 2014 [34] | Australia | 2010a | TIV | Type A/H1N1 | 43% (9.9–81.6) (3/7) | 100% (83.2–100) (20/20) |
Chuaychoo et al., 2010 [31] | Thailand | 2006–2007 | TIV | All subjects |  |  |
 Type A/H1N1 | 80.0% (69.6–87.5) (60/75) | 93.3% (85.1–97.1) (70/75) | ||||
 Type A/H3N2 | 84.0% (74.1–90.6) (63/75) | 88.0% (78.7–93.6) (66/75) | ||||
 Type B | 61.3% (50.0–71.5) (46/75) | 72.0% (61.0–80.9) (54/75) | ||||
Subjects > 60 year |  |  | ||||
 Type A/H1N1 | 79.7% (68.8–87.5) (55/69) | 94.2% (86.0–97.7) (65/69) | ||||
 Type A/H3N2 | 84.1% (73.7–90.9) (58/69) | 88.4% (78.8–94.0) (61/69) | ||||
 Type B | 59.4% (47.6–70.2) (41/69) | 71.0% (59.4–80.4) (49/69) | ||||
Gorse et al., 2004 [32] | US | 1998–1999 | TIV + placebo |  Type A/H1N1 | 59.4% (40.6–76.3) (19/32) | - |
 Type A/H3N2 | 53.1% (34.7–70.9) (17/32) | - | ||||
 Type B | 34.4% (18.6–53.2) (11/32) | - | ||||
Wongsurakiat et al., 2004 [35] | Thailand | 1997–1998 | TIV (2 doses)b |  Type A/H1N1 | 80.0% (67.7–89.2) (48/60)‡ | 76.6% (64.0–86.6) (46/60) |
 Type A/H3N2 | 76.7% (64.0–86.6) (46/60)‡ | 86.7% (75.4–94.1) (52/60) | ||||
 Type B | 50.0% (36.8–63.2) (30/60)‡ | 45.0% (32.1–58.4) (27/60) | ||||
Gorse et al., 1997 [33] | US | 1994–1995 | TIV + placebo |  Type A/H1N1 | 46.2% (19.2–74.9) (6/13) | - |
 Type A/H3N2 | 61.5% (31.6–86.1) (8/13) | - | ||||